Afuco™ Anti-IL22 ADCC Therapeutic Antibody (Fezakinumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant human monoclonal antibody expressed in CHO binding to human IL22. Fezakinumab is a human monoclonal antibody against interleukin-22, designed for the treatment of psoriasis and rheumatoid arthritis.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-TAB-748 |
| Pricing | Inquiry |
| Host | Human |
| Target | IL22 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Applications | IP, IF, FuncS, FC, Neut |
| Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |